Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results
Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results Agreement reached with Merck KGaA to gain back the full rights of NMS-293 Available clinical data support NMS-293 as an ideal partner for combination with DNA-damaging agents like chemotherapies or ADC payloads: NMS […]
Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts
Perron U, Grassi E, Chatzipli A, Viviani M, Karakoc E, Trastulla L, Brochier LM, Isella C, Zanella ER, Klett H, Molineris I, Schueler J, Esteller M, Medico E, Conte N, McDermott U, Trusolino L, Bertotti A, Iorio F Nat Commun (2024), 15(1), 9139
New LsrK Ligands as AI-2 Quorum Sensing Interfering Compounds against Biofilm Formation
Milli G, Pellegrini A, Listro R, Fasolini M, Pagano K, Ragona L, Pietrocola G, Linciano P, Collina S Med Chem (2024), 67(20), 18139-18156
Nerviano Medical Sciences Announces Strategic acquisition of atamparib, a Phase II-ready PARP7 Inhibitor, from Ribon Therapeutics
NERVIANO, Italy and BOSTON, Mass., November 14, 2024 – Nerviano Medical Sciences S.r.l. (NMS) – a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Srl – a global leader in oncological innovation with a leading position in PARP1 inhibitor clinical development in brain cancer, is […]
Nerviano Medical Sciences at BIO-Europe 2024
Nerviano Medical Sciences is excited to announce the participation in BIO-Europe 2024, Europe’s premier life sciences partnering event. – In-Person Event: November 4–6, 2024, Stockholm, Sweden – Digital Partnering: November 12–13, 2024 We look forward to meeting you at the event and discussing potential collaborations. Please click here for more details and to connect with […]
Nerviano Medical Sciences announces publication of the paper “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents”
We are pleased to announce the publication of our review article titled “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents” in Pharmaceuticals, as part of the Special Issue “Evaluation of the Antitumor Mechanism of Armed Antibodies: 2nd Edition“. This paper explores the latest advances in the use of DNA-interacting agents […]
We are speaking at the 15th Annual WADC San Diego 2024!
We are speaking at the 15th Annual WADC 2024 in San Diego . partnering event in San Diego , 4 – 7 Nov. 2024 We look forward to your presence to explore future partnership opportunities. * * * * * Contact: Valsasina Barbara : Barbara.Valsasina@demo111.axxiem.com Lupi Rosita: rosita.lupi@demo111.axxiem.com * * * * * About NMS […]
NMS Group S.p.A. Announces Change in Shareholding Structure, Board of Directors and Statutory Auditors to Accelerate Growth and Innovation
NERVIANO, IT, September 11, 2024 – NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces today a change to its shareholding structure, leading to a restructured board of directors and statutory auditors. The Fondazione Regionale per la Ricerca Biomedica (FRRB), established by the Lombardy Regional Government with an aim to promote […]
NMS-UPO paper featured on the cover of Chemistry A European Journal
Turning the Impossible into Reality: A chemical astronaut harnesses blue light irradiation to activate Passerini products containing a Hantzsch ester, derived from what are considered “impossible aldehydes.” Be sure to check out the stunning artwork created by Francesca Brunelli, one of the authors of our latest paper in collaboration with Prof. Professor Tron (Università del […]
Nerviano Medical Sciences S.r.l. Announces BRAFTOVI® Royalty Agreement with Blue Owl Capital, potentially exceeding $80 Million
– NMS to receive in excess of $50 Million in upfront cash and milestone payments; total returns capped at a multiple of investment – Financing proceeds will be used to advance NMS’ current pipeline and ADC platform NERVIANO, Italy and BOSTON, Mass., September 5 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) […]